An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors
Robert M. Jotte(Sarah Cannon), Robert Ilaria(Eli Lilly (United States)), Donald Richards(The US Oncology Network), P. Kellie Turner(Eli Lilly (United States)), Lawrence Garbo(New York Oncology Hematology), Daniel D. Von Hoff(Translational Genomics Research Institute), Paul Conkling(Virginia Oncology Associates), Jian Chen(University of Science and Technology of China), David A. Smith(SUNY Upstate Medical University), Joe Stephenson(Neurology Centers of the Carolinas), Fadi Braiteh(Opexa Therapeutics (United States)), Carlos Becerra(Texas Oncology), D. F. Tai(Eli Lilly (United States)), Kay Hoong Chow(Eli Lilly (United Kingdom)), Francisco Robert-Vizcarrondo(University of Alabama at Birmingham)
Cited by 10
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
|Science|2017|1.8k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k